Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder
Publication date
2013-01Author
Sutherland, MarkGill, Jason H.
Loadman, Paul
Laye, Jonathan P.
Sheldrake, Helen M.
Illingworth, Nicola A.
Alandas, Mohammed N.
Cooper, Patricia A.
Searcey, M.
Pors, Klaus
Shnyder, Steven
Patterson, Laurence H.
Keyword
AnimalsAntineoplastic agents
Biotransformation
CHO cells
Carcinoma
Cell line; Tumor
Cell survival
Cricetinae
Cytochrome P-450 CYP1A1
Female
Gene expression
Humans
Indoles
Liver
Maximum tolerated dose
Mice
Inbred BALB C
Microsomes
Pyrroles
Tumor burden
Urinary bladder neoplasms
Xenograft model antitumor assays
REF 2014
Metabolism
Pharmacokinetics
Pharmacology
Transitional cell
Drug therapy
Enzymology
Pathology
Genetics
Peer-Reviewed
Yes